Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

Patient-Focused Drug Development Listening Meeting — Patient Perspectives on Gene Therapy Products (Cell and Gene Therapy Catapult – Regulatory Round-up – November 2022)

Patients and caregivers can provide valuable input into the discussion of investigational therapies by describing their experience with a disease or condition, and by defining meaningful change in terms of their specific disease and the risks they are willing to accept. With the potential for more gene therapies to become available to patients in the future, it is important to understand patient and caregiver perspectives on these products.

The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) hosted a virtual patient-focused drug development listening meeting to better understand patient perspectives on gene therapy products, including cell-mediated gene therapies.

The recording can be viewed here.

See all of Catapult’s Regulatory Round-up for November 2022 here. Published on the 8th of December 2022.


OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (25 janvier 2023). Patient-Focused Drug Development Listening Meeting — Patient Perspectives on Gene Therapy Products (Cell and Gene Therapy Catapult – Regulatory Round-up – November 2022). ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/o67r


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.